OrbiMed’s Annexon ANNX Stock Holding History

OrbiMed’s Portfolio ANNX Stock Details ANNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-379,947	Closed	-$11.5M	–	151
2020 Q3	$11.5M	Buy	+379,947	New	+$8.91M	0.14%	106

Other funds holding ANNX

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

AIM

Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

OrbiMed's ANNX Position: Q4 2020 in Review

OrbiMed sold out of Annexon (ANNX) in Q4 2020, closing a stake of 379,947 shares — an estimated $11.5M sold.

OrbiMed first reported a position in ANNX in Q3 2020 and held it in 1 quarter. The position peaked at $11.5M in Q3 2020. 70 funds tracked by Wall St. Rank hold ANNX as of Q4 2020.

OrbiMed reported no remaining Annexon position as of Q4 2020 after selling out during the quarter.
OrbiMed sold 379,947 Annexon shares in Q4 2020, an estimated $11.5M.
OrbiMed first reported a position in Annexon in Q3 2020 and held it in 1 quarter.
OrbiMed's Annexon position peaked at $11.5M in Q3 2020.
70 funds tracked by Wall St. Rank held Annexon as of Q4 2020.

Based on OrbiMed's 13F filing for Q4 2020, filed 16 Feb 2021.